Literature DB >> 6648866

Effects of verapamil on pulmonary haemodynamics during hypoxaemia, at rest, and during exercise in patients with chronic obstructive pulmonary disease.

S E Brown, G S Linden, R R King, G P Blair, D W Stansbury, R W Light.   

Abstract

The haemodynamic effects of intravenous verapamil at rest, during hypoxaemia, and during progressive exercise were evaluated in 10 patients with chronic obstructive lung disease. Verapamil produced significant decreases in the peak heart rate and systemic blood pressure during exercise but exercise capacity and pulmonary gas exchange at exhaustion were unaffected. There were no significant changes in pulmonary artery pressure or total pulmonary vascular resistance during exercise or during the breathing of either air or a hypoxic gas mixture at rest. No clinically useful benefit was found with verapamil in the dosage used in this group of patients and the value of calcium antagonists in the treatment of patients with chronic obstructive lung disease requires further clarification.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6648866      PMCID: PMC459673          DOI: 10.1136/thx.38.11.840

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  17 in total

1.  Osteopathy.

Authors:  W B Parsons
Journal:  Can Med Assoc J       Date:  1982-02-01       Impact factor: 8.262

2.  [Clinical experimental studies on the blood pressure reducing effect of verapamil].

Authors:  W D Brittinger; A Schwarzbeck; K W Wittenmeier; W D Twittenhoff; B Stegaru; W Huber; R W Ewald; G E von Henning; M Fabricius; M Strauch
Journal:  Dtsch Med Wochenschr       Date:  1970-09-11       Impact factor: 0.628

3.  [Isoptin in the therapy of tachycardiac type of atrial flutter].

Authors:  F Bender
Journal:  Med Klin       Date:  1967-04-21

4.  Inhibition of hypoxic pulmonary vasoconstriction by nifedipine.

Authors:  G Simonneau; P Escourrou; P Duroux; A Lockhart
Journal:  N Engl J Med       Date:  1981-06-25       Impact factor: 91.245

5.  Pulmonary vascular effects of verapamil.

Authors:  A Davidson; I McMurtry; J T Reeves
Journal:  Am Heart J       Date:  1978-06       Impact factor: 4.749

6.  Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men.

Authors:  J H Atterhög; L G Ekelund
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

7.  Prolyl hydroxylase activity in normal and diseased human liver.

Authors:  G C Fuller; J C Nolan
Journal:  Proc Soc Exp Biol Med       Date:  1976-01

8.  Verapamil and pulmonary hypertension.

Authors:  K Landmark; A M Refsum; S Simonsen; O Storstein
Journal:  Acta Med Scand       Date:  1978

9.  Primary pulmonary hypertension: effects of nifedipine.

Authors:  F Camerini; E Alberti; S Klugmann; A Salvi
Journal:  Br Heart J       Date:  1980-09

10.  Angiotensin, hypoxia, verapamil and pulmonary vessels.

Authors:  A J Suggett; F H Mohammed; G R Barer
Journal:  Clin Exp Pharmacol Physiol       Date:  1980 May-Jun       Impact factor: 2.557

View more
  5 in total

Review 1.  Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia.

Authors:  Larissa A Shimoda
Journal:  Physiology (Bethesda)       Date:  2020-07-01

Review 2.  Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series).

Authors:  Bradley A Maron; Roberto F Machado; Larissa Shimoda
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 3.  Pulmonary hypertension.

Authors:  J R Michael; W R Summer
Journal:  Lung       Date:  1985       Impact factor: 2.584

Review 4.  Can pulmonary vasodilators improve survival in cor pulmonale due to hypoxic chronic bronchitis and emphysema?

Authors:  K F Whyte; D C Flenley
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

5.  Vasodilators in pulmonary hypertension.

Authors:  A Peacock
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.